Loading...
 

July - September 2017:
Volume 30, Issue 3

Click on the image to download the Issue in PDF format.

ARCHIVE

Pneumon 2017, 30(3):133-140
Recurrence in patients that underwent surgery for lung cancer
Authors Information
1: Thoracic Surgery Department of «Sotiria» Athens Chest Diseases Hospital, Athens, Greece
2: 10th Department of Respiratory Medicine of «Sotiria» Athens Chest Diseases Hospital, Athens, Greece
3: Oncology Department of 3rd University Medical Clinic of «Sotiria», Athens, Greece
References
  1. GBD 2015 Mortality and Causes of Death Collaborators, “Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet (London, England), 2016; 388:1459–544.
  2. Heron M, Anderson RN. Changes in the Leading Cause of Death: Recent Patterns in Heart Disease and Cancer Mortality. NCHS Data Brief 2016; 254:1–8.
  3. Malvezzi, M Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2013. Ann Oncol Off J Eur Soc Med Oncol 2013; 24:792–800.
  4. Wright G, Manser RL, Byrnes G, Hart D, Campbell DA. Surgery for non-small cell lung cancer: systematic review and meta-analysis of randomised controlled trials. Thorax 2006; 61:597–603.
  5. Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143(Suppl):e278S–313S.
  6. Fedor D, Johnson WR, Singhal S. Local recurrence following lung cancer surgery: incidence, risk factors, and outcomes. Surg Oncol 2013; 22:156–61.
  7. Moro-Sibilot D, Audigier-Valette C, Merle P, et al. Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study). Lung Cancer 2015; 89:139–45.
  8. Lou F, Huang J, Sima CS, Dycoco J, Rusch V, Bach PB. Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance. J Thorac Cardiovasc Surg 2013; 145:75-81.
  9. Lang-Lazdunski L. Surgery for nonsmall cell lung cancer. Eur Respir Rev 2013; 22:382–404.
  10. Lim E, Baldwin D, Beckles M, et al. Guidelines on the radical management of patients with lung cancer. Thorax 2010; 65(Suppl 3):1-27.
  11. Ha D, Choi H, Chevalier C, Zell K, Wang X-F, Mazzone PJ. Survival in patients with metachronous second primary lung cancer. Ann Am Thorac Soc 2015; 12:79–84.
  12. Consonni D, Pierobon M, Gail MH, et al. Lung cancer prognosis before and after recurrence in a population-based setting. J Natl Cancer Inst 2015; 107:djv059.
  13. Colombi D, Di Lauro E, Silva M, et al. Non-small cell lung cancer after surgery and chemoradiotherapy: follow-up and response assessment. Diagn Interv Radiol 2013; 19:447–56.
  14. De Zoysa MK, Hamed D, Routledge T, Scarci M. Is limited pulmonary resection equivalent to lobectomy for surgical management of stage I non-small-cell lung cancer? Interact Cardiovasc Thorac Surg 2012; 14:816–20.
  15. Bonnette P. Sublobar curative resection for non-small-cell lung cancer. Bull Cancer 2012; 99:1069–75.
  16. Cao C, Gupta S, Chandrakumar D, Tian DH, Black D, Yan TD. Meta-analysis of intentional sublobar resections versus lobectomy for early stage non-small cell lung cancer. Ann Cardiothorac Surg 2014; 3:134–41.
  17. Huang X, Wang J, Chen Q, Jiang J. Mediastinal lymph node dissection versus mediastinal lymph node sampling for early stage non-small cell lung cancer: a systematic review and meta-analysis. PLoS One 2014; 9:e109979.
  18. Korasidis S, Menna C, Andreetti C, et al. Lymph node dissection after pulmonary resection for lung cancer: a mini review. Ann Transl Med 2016; 4:368.
  19. HG Colt, SD Murgu, RJ Korst, CG Slatore, M Unger, S Quadrelli. Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143(Suppl): e437S–54S.
  20. Kelsey CR, Higgins KA, Peterson BL, et al. Local recurrence after surgery for non-small cell lung cancer: a recursive partitioning analysis of multi-institutional data. J Thorac Cardiovasc Surg 2013; 146:768–73, e1.
  21. Kidane B, Toyooka S, Yasufuku K. MDT lung cancer care: input from the Surgical Oncologist. Respirology 2015; 20:1023–33.
  22. Yano T, Okamoto T, Fukuyama S, Maehara Y. Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer. World J Clin Oncol 2014; 5:1048–54.
  23. Heon S, Johnson BE. Adjuvant chemotherapy for surgically resected non-small cell lung cancer. J Thorac Cardiovasc Surg 2012, 144:S39-42.
  24. Greene F, Page D, Fleming I, Fritz A. American Joint Committee on Cancer. AJCC cancer staging 2002, pp. 387–90.
  25. Darling GE, Allen MS, Decker PA, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphad-enectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non–small cell carcinoma: Results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg 2011; 141:662–70.
  26. Osarogiagbon RU, Decker PA, Ballman K, Wigle D, Allen MS, Darling GE. Survival Implications of Variation in the Thorough-ness of Pathologic Lymph Node Examination in American College of Surgeons Oncology Group Z0030 (Alliance). Ann Thorac Surg 2016; 102:363–9.
  27. Demicheli R, Fornili M, Ambrogi F, et al. Recurrence dynamics for non-small-cell lung cancer: effect of surgery on the devel-opment of metastases. J Thorac Oncol 2012; 7:723–30.
  28. Yamauchi Y, Muley T, Safi S, et al. The dynamic pattern of recurrence in curatively resected non-small cell lung cancer patients: Experiences at a single institution. Lung Cance 2015; 90:224–9.
  29. Zhu JF, Feng XY, Zhang XW, et al. Time-varying pattern of postoperative recurrence risk of early-stage (T1a-T2bN0M0) non-small cell lung cancer (NSCLC): results of a single-center study of 994 Chinese patients. PLoS One 2014; 9:e106668.
  30. Deng XF, Liu QX, Zhou D, Min JX, Dai JG. Bone marrow micro-metastasis is associated with both disease recurrence and poor survival in surgical patients with node-negative non-small-cell lung cancer: a meta-analysis. Interact Cardiovasc Thorac Surg 2015; 21:21–7.
  31. Deng XF, Jiang L, Liu QX, et al. Lymph node micrometastases are associated with disease recurrence and poor survival for early-stage non-small cell lung cancer patients: a meta-analysis. J Cardiothorac Surg 2016; 11:28.
  32. Coello MC, Luketich JD, Litle VR, Godfrey TE. Prognostic signifi-cance of micrometastasis in non-small-cell lung cancer. Clin Lung Cancer 2004; 5:214–25.
  33. Wang B, Wang B, Zhang D, Guo H, Zhang L, Zhou W. Clinical test on circulating tumor cells in peripheral blood of lung cancer patients, based on novel immunomagnetic beads. Artif cells, nanomedicine, Biotechnol 2016; 44:892–7.
  34. Stojiljkovic D, Mandaric D, Miletic N et al. Characteristics of local recurrence of lung cancer and possibilities for surgical management. J BUON 2013; 18:169–75.
  35. Ohtaki Y, Shimizu K, Kaira K, et al. Risk factors associated with recurrence of surgically resected node-positive non-small cell lung cancer. Surg Today 2016; 46:1196–208.
  36. Kozu Y, Maniwa T, Takahashi S, Isaka M, Ohde Y, Nakajima T. Risk factors for both recurrence and survival in patients with pathological stage I non-small-cell lung cancer. Eur J Cardio-thorac Surg 2013; 44:e53-8.
  37. Koo H-K, Jin SM, Lee CH, et al. Factors associated with recur-rence in patients with curatively resected stage I-II lung cancer.
  38. Wu CF, Fu JY, Yeh CJ, et al. Recurrence risk factors analysis for stage I non-small cell lung cancer. Medicine (Baltimore) 2015; 94:e1337.
  39. Sestini S, Boeri M, Marchiano A, et al. Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening. Oncotarget 2015; 6:32868–77.
  40. Wang B, Song N, Yu T, et al. Expression of tumor necrosis factor-alpha-mediated genes predicts recurrence-free survival in lung cancer. PLoS One 2014; 9:e115945.
  41. Yoon KA, Yoon H, Park S, et al. The prognostic impact of micro-RNA sequence polymorphisms on the recurrence of patients with completely resected non-small cell lung cancer. J Thorac Cardiovasc Surg 2012; 144:794–807.
  42. He J, Shen J, Yang C, et al. Adjuvant chemotherapy for the completely resected stage IB nonsmall cell lung cancer: A systematic review and meta-analysis. Medicine (Baltimore) 2015; 94:e903.
  43. Byron E, Pinder-Schenck M. Systemic and targeted therapies for early-stage lung cancer. Cancer Control 2014; 21:21–31.
  44. Le Péchoux C, Mercier O, Belemsagha D, Bouaita R, Besse B, Fadel E. Role of adjuvant radiotherapy in completely resected non-small-cell lung cancer. EJC Suppl, EJC Off J EORTC, Eur Organ Res Treat Cancer 2013; 11:123–30.
  45. Suda K, Mitsudomi T. Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond. Lung Cancer (Auckland NZ), 2013; 4:43–53.
  46. Steuer CE, Khuri FR, Ramalingam SS. The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer. Cancer 2015; 121:E1-6.
  47. Lima ABC, Macedo LT, Sasse AD. Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis. PLoS One 2011; 6:e22681.
  48. Steven A, Fisher SA, Robinson BW. Immunotherapy for lung cancer. Respirology 2016; 21:821–33.
  49. Kelly K, Altorki NK, Eberhardt WE, et al. Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): A randomized, double-blind, phase III. Trial J Clin Oncol 2015; 33:4007–14.
  50. Gridelli C, Bareschino MA, Schettino C, Rossi A, Maione P, Ciardiello F. Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist 2007; 12:840–9.
  51. Takeda K, Hida T, Sato T, et al. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib com-pared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial. J Clin Oncol 2010; 28:753–60.